For individuals living with chronic conditions, stable housing enables consistent care. Conversely, housing instability can disrupt care continuity, increase financial strain, and contribute to ...

Dismissals occurred in 432 of 174,250 patients (0.25%), with noncompliance (60.2%) and aggressive or inappropriate conduct (18.2%) comprising the majority of cited reasons. Demographic differences ...

Retrospective Cleveland Clinic data (89 eyes) linked branded-to-bevacizumab switching with increased CST, shortened median injection interval (8.6 to 7.5 weeks), and 15.7% meeting poor-outcome ...

State-by-state Medicaid payment differed markedly, with 34 states (82% of enrollees) paying less than Medicare and 18 states paying under 80% of Medicare. Extremes included Nebraska at 184% of ...

IRIS Registry analysis captured first faricimab injections from Feb 2022–Sep 2023, requiring ≥12 months pre-index data and ≥24 months follow-up to characterize longitudinal real-world utilization.

There will be a greater focus on surgical topics at the 2025 meeting of the American Society of Retina Specialists, compared with previous years, which reflects the need for balan ...

Aimée K. Dailey, president of Government Health Benefits at Elevance Health | Authors | Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and ...

Ambient-stable microneedle patches are positioned as a route to reduce refrigeration dependence and simplify administration ...

Bevacizumab reached 29.8% of 2025 injections, rising from 23.3% in 2024, while aflibercept 2 mg fell to 21.9% from 36.9% in 2024. Reduced Good Days copay assistance disrupted affordability for branded ...

FDA authorization positions enlicitide as the first oral PCSK9 inhibitor, targeting PCSK9–LDLR interaction via macrocyclic peptide binding to deliver substantial LDL-C lowering in a daily pill ...

Monthly Eylea HD addresses a subset needing more frequent anti-VEGF than the ≥8‑week minimum used in PULSAR/PHOTON, including patients previously underperforming on aflibercept 8 mg q7–8w. ELARA is an ...